ClinicalTrials.gg
CompletedNCT03255785Updated Sep 9, 2022

Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One iStent and One iStent Supra

An interventional study of Cataract surgery plus one iStent and one iStent Supra implanted in Glaucoma, Open-Angle, sponsored by Glaukos Corporation. Completed at 1 site in Armenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-09.

Sponsored by Glaukos Corporation · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies in Glaucoma, Open-Angle by Glaukos Corporation — 7 open to participants now, 10 under way, 2 of them phase 3. Glaucoma, Open-Angle · Glaukos Corporation.

Enrollment
36th of 38
15 · median 111
Started
2018
with 3 others
No phase
15 of 43
none open now
Registered
26th of 43
by date

Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, this one is the 36th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2018, is one of 15 with no phase, and was the 26th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

7 of the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, or all of them as a file.
02

Study summary

Open Angle Glaucoma Subjects with Cataract treated with Cataract Surgery plus one trabecular micro-bypass stent and one suprachoroidal stent

03

Conditions studied

  • Glaucoma, Open-Angle

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • cataract requiring surgery Primary open-angle or pseudoexfoliative glaucoma Visual field defects no worse than -12dB Subject on two ocular hypotensive medications at screening Medicated IOP at screening between 18 and 30 mm Hg Normal iridocorneal anatomy Absence of peripheral anterior synechiae

Exclusion criteria

Exclusion Criteria:

  • Monocular subjects or those with wore than 20/200 vision in fellow eye Prior stent implantation, incision glaucoma surgery, or laser trabeculoplasty in study eye Traumatic, uveitic, or neovascular glaucoma
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    G1 plus G3 with phaco

    Cataract surgery via phacoemulsification followed by implantation of one iStent and one iStent Supra

    Device: Cataract surgery plus one iStent and one iStent Supra implanted

Interventions

  • DeviceCataract surgery plus one iStent and one iStent Supra implanted

    Cataract surgery via phacoemulsfication plus one iStent and one iStent supra

06

What researchers measure

Primary outcomes

  1. 20% IOP reduction from baseline

    IOP measured via Goldmann tonometry in mm Hg and compared to baseline IOP

    Time frame: Month 12

Secondary outcomes

  1. IOP less than or equal to 18 mm Hg

    IOP measured via Goldmann tonometry in mm Hg

    Time frame: Month 12

07

Study locations

1 site
  • Glaukos Investigator Sites
    Yerevan, Armenia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Dec 2019, 19 months.

Of 70 industry-sponsored interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's 19 months is below that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2017
First posted
Aug 21, 2017
StartActual
May 1, 2018
Primary completionActual
Dec 3, 2019
CompletionActual
Dec 3, 2019
Last update
Sep 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03255785
Responsible party
Sponsor
First posted
Aug 21, 2017
Start date
May 1, 2018
Primary completion
Dec 3, 2019
Completion
Dec 3, 2019
Last update
Sep 9, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion